- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Diagnosis and Prevalence of Demodex Blepharitis
Neda Shamie, MD, summarizes the prevalence and clinical manifestations of Demodex Blepharitis.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of an Insights involving Neda Shamie, MD.
Until recently, there were no FDA-approved therapies for Demodex blepharitis. In the past, Demodexblepharitis was quite common but often left untreated for years. Various abrasive in-office procedures, home therapies encouraging patients to abrade their own eyelashes/eyelids, and chemical cleansers were tried to lessen the Demodexload, but none treated the root cause. These approaches often irritated patients more than the actual disease.
Demodexblepharitis is highly prevalent, with a recent study finding that 56% of cataract patients had pathognomonic signs, even without symptoms. Over 90% of patients intolerant of contact lenses and 60% of those on dry eye treatment had Demodex, indicating it is an underdiagnosed condition.
Diagnosing Demodexblepharitis is simple. The eye care specialist uses a slit lamp to look at the patient’s eyelash line. When the patient looks down, the doctor examines the eyelash base for collarettes, which are mite excretions that cluster and cake on the lashes. This can cause inflammation, hair follicle loss, and other issues.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More
